2026-07-17T12:20:59Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/119182026-07-17T00:05:28Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

00925njm 22002777a 4500 dc Casajús, Ana author Zubiaur, Pablo author Alday, Enrique author Soria‐Chacartegui, Paula author Saiz‐Rodríguez, Miriam author Gutierrez, Lara author Aragonés, Catalina author Campodónico, Diana author Gómez‐Fernández, Antía author Navares‐Gómez, Marcos author Villapalos‐García, Gonzalo author Mejía‐Abril, Gina author Ochoa, Dolores author Abad‐Santos, Francisco author 2024-01 Tramadol is an important minor opioid prescribed for pain management. In this study, we analyzed the well-known impact of CYP2D6 genetic variation and 60 additional variants in eight candidate genes (i.e., ABCG2, SLCO1B1, CYP2D6, CYP2B6, CYP2C19, CYP2C9, CYP3A5, and CYP3A4) on tramadol efficacy and safety. Some 108 patients with pain after surgery admitted to a post-anesthesia care unit (PACU) and prescribed tramadol were recruited. They were genotyped, and tramadol M1/M2 metabolite concentrations were determined by a newly validated HPLC-MS/MS method. CYP2D6 intermediate (IM) and poor (PM) metabolizers showed lower M1 concentrations adjusted for dose/weight at 30 and 120 min compared to ultrarapid (UM) and normal (NM) metabolizers (univariate p < 0.001 and 0.020, multivariate p < 0.001 and 0.001, unstandardized β coefficients = 0.386 and 0.346, R2 = 0.146 and 0.120, respectively). CYP2B6 PMs (n = 10) were significantly related to a higher reduction in pain 30 min after tramadol intake (univariate p = 0.038, multivariate p = 0.016, unstandardized β coefficient = 0.224, R2 = 0.178), to lower PACU admission time (p = 0.007), and to lower incidence of adverse drug reactions (p = 0.038) compared to the other phenotypes. CYP3A4 IMs and PMs showed a higher prevalence of drowsiness and dizziness (p = 0.028 and 0.005, respectively). Our results suggest that the interaction of CYP2B6 and CYP2D6 phenotypes may be clinically relevant, pending validation of these results in large, independent cohorts. Additional research is required to clarify the impact of CYP3A4 genetic variation on tramadol response. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THIS TOPIC? Nowadays, CYP2D6 is considered the only clinically relevant pharmacogenetic biomarker for tramadol prescription; however, polymorphism of other metabolizing enzymes may be clinically relevant. WHAT QUESTION DID THIS STUDY ADDRESS? In this work, CYP2B6 genotype-informed phenotype was related to the response and tolerability to tramadol in patients with acute post-surgical pain. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? CYP2B6 phenotype may be more relevant than previously thought in relation to tramadol prescription; our results suggest that the interaction of CYP2B6 and CYP2D6 phenotypes may be clinically relevant, pending validation of these results in large, independent cohorts. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? CYP2D6 was the main predictor of tramadol M1 metabolite concentrations but had a modest impact on drug effectiveness and safety. 1752-8054 https://hdl.handle.net/10259/11918 10.1111/cts.13698 1752-8062 Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post‐surgical pain